Xtant Medical Holdings Inc (XTNT)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
The Biotechnology & Pharmaceuticals company declared Sharp Top-line elevation , during the first quarter of 2023
company recorded first quarter of 2023 operating shortfall of $-1.576 million
Published 2023-05-17T04:53:46+00:00
Goran Soko / CSIMarket.com Contributer
![Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons")
XTNT lost money at $-0.02 per share in the first quarter of 2023, although its revenue surged by 38.46 % to $17.94 million from the comparable quarter a year prior. In the preceding quarter XTNT realized Revenue of $15.27 million and $-0.02 per share.
In the most recent fiscal period Xtant Medical Holdings Inc reported net shortfall of $-2.078 million, instead of deficit of $-2.213 million in the comparable quarter a year ago.
Xtant Medical Holdings Inc is expected to report next financial results on August 03, 2023.
Other XTNT's Earnings Reports
The Diminishing Returns have widen more at the amid the financial span closing September 30 2022
Shortfall Despite of Revenues elevation at in the April to June 30 2022 span
Loss larger than a year ago but Topline was Up moderately at in the financial first quarter of 2022
Other XTNT's Earnings Reports
The Diminishing Returns have widen more at the amid the financial span closing September 30 2022
Shortfall Despite of Revenues elevation at in the April to June 30 2022 span
Loss larger than a year ago but Topline was Up moderately at in the financial first quarter of 2022